Peptide News Forum

Cerebrolysin

Cerebrolysin is a mixture of enzymatically treated peptides and free amino acids derived from purified pig brain proteins. It is used primarily as an adjuvant therapy to protect, repair, and improve brain function following acute neurological injuries or during chronic neurodegenerative decline. It mimics the actions of naturally occurring brain growth factors to support the central nervous system.

Key Benefits

  • May support brain cell repair and neuroprotective activity
  • Commonly researched for cognitive support, memory, and mental clarity
  • May help support recovery following neurological stress or injury
  • Research suggests potential benefits for learning capacity, focus, and healthy brain aging

FDA-Approved Uses

Cerebrolysin is NOT approved by the FDA and is NOT approved for sale or distribution in the United States. It is a fully approved prescription medication in 44+ countries including Austria, Germany, China, Russia, and South Korea.

FDA Status: Not registered. No NDA filed. No active US clinical trial program targeting FDA approval as of May 2026. Not classifiable under the 503A compounding framework (complex biological mixture from porcine tissue, not a defined synthetic peptide).

Approved indications in countries where registered:

  1. Acute Ischemic Stroke: Treatment and rehabilitation support
  2. Traumatic Brain Injury (TBI): Cognitive and functional recovery
  3. Alzheimer’s Disease and other dementias: Cognitive symptom management
  4. Vascular dementia: Cognitive function support

Conditions studied in published RCTs

  • Alzheimer’s disease (meta-analysis of 6 RCTs — positive vs. placebo)
  • Vascular dementia
  • Acute ischemic stroke recovery
  • Moderate-to-severe TBI
  • Parkinson’s disease (limited data)
  • ADHD in children (limited data, some countries)

Trade Names in USA and Manufacturers

Global brand and manufacturer:
– Cerebrolysin® — EVER Neuro Pharma GmbH (Unterach am Attersee, Austria)
[Previously Schwarz Biosciences; acquired by EVER Pharma group]

Formulations (where approved internationally):

  • 1 mL ampoule (215.2 mg)
  • 2 mL ampoule (430.4 mg)
  • 5 mL ampoule (1,076 mg)
  • 10 mL ampoule (2,152 mg)
  • 20 mL ampoule (4,304 mg)
  • Concentration: 215.2 mg/mL

US availability:

  • Not legally available through US pharmacies or compounding pharmacies
  • Some patients import from international sources (personal-use grey area)
  • Some US telehealth/wellness clinics administer imported Cerebrolysin off-label
  • Not compoundable under 503A framework (complex biological mixture)

Composition:

  • 15% low-MW bioactive peptides (<10 kDa) that cross the blood-brain barrier
  • 85% free amino acids
  • Active fraction contains peptides mimicking BDNF, NGF, GDNF, CNTF
  • Source: Enzymatic hydrolysis of purified porcine cortical brain tissue

Dosage

Dosing established only in countries where Cerebrolysin is approved.

Route: IV infusion (clinical doses); IM injection (maintenance)

Acute Ischemic Stroke

  • 10–30 mL/day IV in 100–250 mL 0.9% NaCl
  • Duration: 21 consecutive days
  • Start within 24–72 hours of stroke onset
  • Higher doses (50–60 mL) studied; benefit appears dose-dependent

Traumatic Brain Injury (TBI)

  • 10 mL/day IV
  • Duration: 30 consecutive days
  • Repeat courses possible after interval

Alzheimer’s Disease / Dementia

  • 10–60 mL/day IV in 100 mL saline
  • Duration: 20–30 consecutive days per course
  • Repeated every 3–6 months (chronic management)
  • Higher doses (30–60 mL) more effective for neuropsychiatric symptoms

Maintenance:
1–5 mL IM, 2–5x weekly between IV courses

Pricing

USA pricing (imported; no FDA-approved channel):

  • 5 mL ampoules (box of 10): ~$50–$150
  • 10 mL ampoules (box of 10): ~$80–$200
  • Standard 21-day stroke course (10 mL/day): ~$200–$600 (medication only)
  • [Excludes clinical administration, IV consumables, physician fees]

US telehealth/wellness clinics:
~$200–$800/course including physician oversight + IV administration fees

International (where approved and insured):

  • Germany/Austria: Covered by statutory health insurance ✅
  • China / Russia / South Korea: Covered by national insurance ✅
  • Eastern Europe: ~$30–$80 per 10-ampoule course

Tips

  • Cerebrolysin is NOT legally sold or distributed in the USA through any regulated channel. Any US source is either imported from abroad or operating outside FDA oversight.
  • Despite not being FDA-approved, Cerebrolysin has SUBSTANTIAL human clinical data — multiple RCTs, meta-analyses, and decades of use in 44+ countries.
  • The 2013 Cochrane review rated evidence quality as ‘very low.’ However, subsequent larger RCTs (2015–2025) have strengthened the evidence base.
  • If seeking US access: Specialized neurological clinics offer IV Cerebrolysin under physician supervision using imported product.
  • EPILEPSY IS A CONTRAINDICATION — patients with seizure disorders must not use Cerebrolysin.
  • IV administration must be slow infusion (15–60 min) — never rapid IV push.
  • Patients with known pork/porcine allergy should avoid — derived from porcine brain tissue.
  • Cerebrolysin is not a controlled substance and is not on the WADA Prohibited List.

Side Effects

Generally well-tolerated in published RCTs. Adverse event rates largely comparable to placebo in controlled trials.

Common (>5%):

  • Nausea and vomiting: Most common; rate-dependent; increased with rapid infusion or high doses
  • Headache
  • Dizziness / lightheadedness
  • Fever (pyrexia)
  • Fatigue

Infusion-related:

  • Injection site reactions (IM): Pain, redness
  • Warm sensation / flushing during IV infusion
  • Rapid administration → significantly increased nausea risk
  • Less common:
  • Urinary tract infection (likely disease-related in stroke/dementia populations)
  • Depression (potentially disease-related)
  • Tremor; agitation

Rare/theoretical:

  • Hypersensitivity reactions: Possible given porcine-derived biological origin
  • Prion risk: Theoretical; EVER Neuro Pharma applies validated viral inactivation and prion-reduction steps. No prion transmission cases reported in decades of clinical use.

Overall: Multiple RCTs and Cochrane review data confirm favorable tolerability. No significant drug-related serious adverse events across multiple controlled trials.

Contraindications

Per international prescribing information (not FDA label):

Contraindicated:
– Epilepsy / seizure disorders: Neurotrophic stimulation may lower seizure threshold
– Severe renal impairment: Amino acid and peptide clearance may be impaired
– Known hypersensitivity to Cerebrolysin or any component
– Porcine/pork allergy: Derived from porcine cortical brain tissue

Use with caution:
– Pregnancy: Not recommended unless absolutely necessary
– Breastfeeding: Not recommended unless absolutely necessary
– Fluid overload / cardiac failure: IV infusion volume must be considered
– Concurrent MAOIs or antidepressants: Possible pharmacodynamic interaction via monoamine pathways; use with caution
– Parkinson’s disease patients: Some interactions with L-DOPA reported; monitor
– Do NOT mix with lipid-containing solutions or electrolyte concentrates in the same infusion

Pharmacology

Cerebrolysin is NOT a single defined peptide. It is a complex standardized biological mixture produced by controlled proteolytic (enzymatic) hydrolysis of purified porcine cortical brain tissue.
Manufacturer: EVER Neuro Pharma GmbH (Austria).

Composition:
– ~15% low-MW bioactive peptides (<10,000 Daltons) that cross the blood-brain barrier
– ~85% free amino acids (metabolic substrates; not directly bioactive)
– Active peptide fraction mimics/stimulates: BDNF, NGF, GDNF, CNTF

Manufacturing standardization:
– Standardized by nitrogen content and biological activity (neurotrophic potency assay)
– Validated viral inactivation and prion-reduction manufacturing steps
– Each batch tested for potency before release

BBB penetration:
– Peptides <10 kDa actively cross the blood-brain barrier
– IV administration ensures rapid systemic + CNS distribution
– IM absorption is slower but achieves CNS penetration

Mechanism of action

Cerebrolysin acts through multiple neuroprotective and neuroregenerative mechanisms:

1. Neurotrophic Factor Mimicry (primary mechanism):
Active peptide fraction mimics endogenous neurotrophic factors:
– BDNF-like: Promotes neuronal survival, synaptic plasticity, LTP (memory formation)
– NGF-like: Supports cholinergic neuron survival (critical in Alzheimer’s)
– GDNF-like: Supports dopaminergic and motor neuron survival
These effects promote neuroplasticity — new neural connections and reorganization after injury.

2. Neuroprotection Against Excitotoxicity:
Reduces glutamate-mediated excitotoxicity (major mechanism of neuronal death in stroke/TBI).
Decreases calcium influx through NMDA-receptor modulation.

3. Anti-Apoptotic Signaling:
Activates PI3K/Akt, MAPK/ERK pro-survival pathways in neurons.
Reduces caspase activation and programmed cell death.

4. Neurogenesis and Synaptic Plasticity:
Promotes neural progenitor cell proliferation and differentiation.
Enhances LTP — cellular basis of learning and memory.

5. Reduction of Secondary Injury Cascade:
Decreases post-injury microglial activation and inflammatory cytokines.
Some preclinical evidence for amyloid-beta clearance (Alzheimer’s relevance).

Result Claims By Different Companies

EVER Neuro Pharma GmbH (published RCTs and regulatory approval data in 44+ countries):

Alzheimer’s Disease:
– Meta-analysis (Ruther et al.; 6 RCTs, mild-to-moderate AD):
Significantly more effective than placebo on ADAS-cog+ cognitive subscale
Effect size comparable to FDA-approved cholinesterase inhibitors
– 2011 European Journal of Neurology RCT (n=133, 24 weeks, moderate-to-severe AD):
Significant improvement on ADAS-cog+ and CIBIC+ vs. placebo
No significant drug-related serious adverse events

Acute Ischemic Stroke:
– Multiple Asian/European RCTs: Improved neurological recovery (NIHSS, mRS, Barthel Index)
– CASTA trial (large multicenter, China): Did not meet primary endpoint in mild-to-moderate stroke; subgroup benefit in moderate-to-severe stroke

TBI:
– RCT data: Improved recovery rates and cognitive function in moderate-to-severe TBI over 30-day course
– 2025 research review: Additional support for neuronal survival via secondary injury mechanism modulation

Manufacturer claim: ‘Cerebrolysin improves the brain’s ability for self-repair — approved in 44 countries.’

Critical independent assessment:
– 2013 Cochrane Review: Rated overall evidence quality as VERY LOW — small samples, short follow-up, high risk of bias, predominantly manufacturer-funded
– Subsequent RCTs (2015–2025) added larger, better-designed data
– Most regulatory approvals are in countries with different evidence thresholds than FDA

⚠️ NOT FDA APPROVED. Not available through regulated US channels.

Disclaimer

This content about “Cerebrolysin” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.